AnnalsofOncology29:2052–2060,2018
doi:10.1093/annonc/mdy264
Publishedonline24July2018
ORIGINAL ARTICLE
Phase III, randomised trial of avelumab versus
physician’s choice of chemotherapy as third-line
treatment of patients with advanced gastric or
gastro-oesophageal junction cancer: primary analysis
of JAVELIN Gastric 300
Y.-J.Bang1*,E.Yan~ezRuiz2,E.VanCutsem3,K.-W.Lee4,L.Wyrwicz5,M.Schenker6,M.Alsina7,M.-H.Ryu8,
H.-C.Chung9,L.Evesque10,S.-E.Al-Batran11,S.H.Park12,M.Lichinitser13,N.Boku14,M.H.Moehler15,
J.Hong16,H.Xiong16,R.Hallwachs17,I.Conti16&J.Taieb18
1DepartmentofInternalMedicine,SeoulNationalUniversityCollegeofMedicine,Seoul,SouthKorea;2UniversidaddelaFrontera,Temuco,Chile;3Departmentof
DigestiveOncology,UniversityHospitalsGasthuisberg/Leuven,KULeuven,Leuven,Belgium;4DepartmentofInternalMedicine,SeoulNationalUniversityCollege
ofMedicine,SeoulNationalUniversityBundangHospital,Seongnam,SouthKorea;5DepartmentofGastrointestinalCancer,M.Sklodowska-CurieMemorialCancer
Center,Warsaw,Poland;6CentruldeOncologieSf.Nectarie,Craiova,Romania;7DepartmentofMedicalOncology,Valld’HebronUniversityHospitalandVall
d’HebronInstituteofOncology,Barcelona,Spain;8DepartmentofOncology,UniversityofUlsanCollegeofMedicine,AsanMedicalCenter,Seoul;9Divisionof
MedicalOncology,YonseiCancerCenter,YonseiUniversityCollegeofMedicine,YonseiUniversityHealthSystem,Seoul,SouthKorea;10DepartmentofMedical
Oncology,CentreAntoineLacassagne,Nice,France;11DepartmentofClinicalOncologyandHematology,KrankenhausNordwest,Frankfurt,Germany;
12DepartmentofMedicine,SamsungMedicalCenter,Seoul,SouthKorea;13DepartmentofChemotherapyandCombinedTherapy,N.N.BlokhinRussian
OncologicalScientificCenter,RussianAcademyofMedicalSciences,Moscow,RussianFederation;14DepartmentofGastrointestinalMedicalOncologyDivision,
NationalCancerCenterHospital,Tokyo,Japan;15DepartmentofInternalMedicine,JohannesGutenbergUniversityMainz,Mainz,Germany;16GlobalClinical
DevelopmentImmuno-Oncology,EMDSerono,Billerica,USA;17GlobalResearch&Development,MerckKGaA,Darmstadt,Germany;18Departmentof
GastroenterologyandDigestiveOncology,Universite´SorbonneParisCite´,ParisDescartesUniversity,GeorgesPompidouEuropeanHospital,Paris,France
*Correspondenceto:DrYung-JueBang,DepartmentofInternalMedicine,SeoulNationalUniversityCollegeofMedicine,101Daehak-ro,Jongno-gu,Seoul03080,South
Korea.Tel:þ82-2-2072-2390;
E-mail:bangyj@snu.ac.kr
Background:Therecurrentlyarenointernationallyrecognisedtreatmentguidelinesforpatientswithadvancedgastriccancer/
gastro-oesophagealjunctioncancer(GC/GEJC)inwhomtwopriorlinesoftherapyhavefailed.Therandomised,phaseIII
JAVELINGastric300trialcomparedavelumabversusphysician’schoiceofchemotherapyasthird-linetherapyinpatientswith
advancedGC/GEJC.
Patients and methods: Patients with unresectable, recurrent, locally advanced, or metastatic GC/GEJC were recruited
at147sitesglobally.Allpatientswererandomisedtoreceiveeitheravelumab10mg/kgbyintravenousinfusionevery2weeks
orphysician’schoiceofchemotherapy(paclitaxel80mg/m2ondays1,8,and15oririnotecan150mg/m2ondays1and15,
eachofa4-weektreatmentcycle);patientsineligibleforchemotherapyreceivedbestsupportivecare.Theprimaryendpoint
wasoverallsurvival(OS).Secondaryendpointsincludedprogression-freesurvival(PFS),objectiveresponserate(ORR),and
safety.
Results: Atotalof371patientswererandomised.ThetrialdidnotmeetitsprimaryendpointofimprovingOS{median,4.6
versus5.0months;hazardratio(HR)¼1.1[95%confidenceinterval(CI)0.9–1.4];P¼0.81}orthesecondaryendpointsofPFS
[median,1.4versus2.7months;HR¼1.73(95%CI1.4–2.2);P>0.99]orORR(2.2%versus4.3%)intheavelumabversus
chemotherapyarms,respectively.Treatment-relatedadverseevents(TRAEs)ofanygradeoccurredin90patients(48.9%)and
131patients(74.0%)intheavelumabandchemotherapyarms,respectively.Grade(cid:2)3TRAEsoccurredin17patients(9.2%)in
theavelumabarmandin56patients(31.6%)inthechemotherapyarm.
VCTheAuthor(s)2018.PublishedbyOxfordUniversityPressonbehalfoftheEuropeanSocietyforMedicalOncology.
ThisisanOpenAccessarticledistributedunderthetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://creativecommons.org/licenses/by-nc/4.0/),whichpermitsnon-commercialre-use,
distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited.Forcommercialre-use,pleasecontactjournals.permissions@oup.com
Original article
Annals ofOncology
Conclusions: Treatment of patients with GC/GEJC with single-agent avelumab in the third-line setting did not result in an
improvementinOSorPFScomparedwithchemotherapy.Avelumabshowedamoremanageablesafetyprofilethan
chemotherapy.
Trialregistration:ClinicalTrials.gov:NCT02625623.
Keywords:PD-L1,avelumab,chemotherapy,gastriccancer,gastro-oesophagealjunctioncancer,phaseIII
Introduction solid tumours, including GC/GEJC [17, 18]. In a cohort of the
phase I JAVELIN Solid Tumor trial, avelumab administered as
Patients with newly diagnosed metastatic gastric cancer/gastro-
first-linemaintenanceorsecond-linetreatmentofpatientswith
oesophageal junction cancer (GC/GEJC) have poor prognosis,
advancedGC/GEJCshoweddurableantitumouractivityandan
with median overall survival (OS) of (cid:3)1year; patients with
acceptablesafetyprofile[19].Avelumabhasalsoshownencour-
previouslytreatedmetastaticGC/GEJChaveevenworseprogno-
aging results in a phase I cohort of Japanese patients with
sis [1–4]. Chemotherapy remains the standard of care for
advanced GC/GEJC that progressed after chemotherapy in the
advancedGC/GEJCandcanprolongsurvivalandimprovequal-
JAVELINSolidTumorJPNtrial[20].
ity of life compared with best supportive care (BSC); however,
Here,wereporttheresultsfromarandomised,phaseIIItrial
mostchemotherapyregimensfailtoprovidesubstantialsurvival
ofavelumabversusphysician’schoiceofchemotherapyasthird-
benefits[3,4].
linetreatmentinpatientswithadvancedGC/GEJC.
ForpatientswithadvancedGC/GEJC,first-linetreatmentwith
platinum and fluoropyrimidine is standard, with trastuzumab
added for patients with HER2þ tumours [5–7]. Preferred Patients andmethods
second-linetreatmentsincludetaxanes,irinotecan,orramuciru-
mab as monotherapy or in combination with paclitaxel [5, 6].
Studydesignandpatients
Although phase III data are lacking, third-line chemotherapy is
widelyutilisedinpatientsinwhompreviouslineshavefailed,es- JAVELIN Gastric 300 (NCT02625623) is a multicentre, international,
pecially in Asia [8]. In the TAGS study, trifluridine/tipiracil randomised,open-label,phaseIIItrialassessingavelumabversusphysi-
improved OS[5.7versus3.6months;HR ¼0.69 (95%CI0.56– cian’schoiceofchemotherapyasathird-linetreatmentofpatientswith
0.85); P¼0.0003] compared with placebo as third-line or later advancedGC/GEJC.Eligiblepatientswererequiredtobeaged(cid:2)18years;
havehistologicallyconfirmedrecurrent,unresectable,locallyadvanced,
therapy for advanced GC [9]. Currently, there are no standard,
ormetastaticGC/GEJC(witheithermeasurableornon-measurabledis-
internationally recognised guidelines for third-line therapy for
ease)forwhichtheyreceivedtwopriorlinesofsystemictreatment;and
patientswithadvancedGC/GEJC,underscoringtheneedforef- anEasternCooperativeOncologyGroupperformancestatusof0or1.
fectivetherapieswithacceptablesafetyprofiles[5,6,8,10]. ExclusioncriteriaincludedpriortreatmentwithT-cellcoregulatorypro-
GC/GEJCisassociatedwithimmunesystemevasionandover- teininhibitors,concurrentanticancertreatment,andconcurrenttreat-
expressionofimmunecheckpointproteins,providingtheration- ment with immunosuppressive agents (see supplementary methods,
availableatAnnalsofOncologyonline).Thetrialwasconductedinac-
aleforimmunotherapywithanti-PD-1/PD-L1therapy[11–14].
cordance with the Declaration of Helsinki and other regulations. The
Elevated expression of PD-L1 has been reported in up to 65%
protocolwasapprovedbytheinstitutionalreviewboardorindependent
of GC/GEJC and is associated with specific subtypes of
ethicscommitteeofeachcentre;allpatientsprovidedwritteninformed
gastricadenocarcinomaandtumourswithhighmutationalbur- consentbeforeparticipation.
den [11–14]. However, there is currently no consensus on the
roleofPD-L1expressionasaprognosticbiomarkerinadvanced Treatment
GC[15].
Allpatientswererandomised1:1toreceiveBSCandeitheravelumab
Initial trial results have demonstrated the clinical activity of
10mg/kgbyintravenousinfusionevery2weeksorphysician’schoiceof
immunotherapy in the third-line setting or beyond in patients
chemotherapy. Premedication with diphenhydramine and acetamino-
withadvancedGC/GEJCinsingle-armstudiesorrandomisedtri- phen was required 30–60min before avelumab infusion. Permitted
alsusingplaceboasthecomparator.Pembrolizumabwasgranted optionsinthechemotherapyarmincludedpaclitaxel80mg/m2ondays
acceleratedapprovalintheUSAforpatientswithPD-L1þGCon 1,8,and15ofa4-weektreatmentcycleoririnotecan150mg/m2ondays
thebasisofacohortofalarge,non-randomised,phaseIIstudy 1and15ofa4-weektreatmentcycle.Patientsrandomisedtothechemo-
therapy arm and deemed ineligible for chemotherapy were allowed to
showing tumour responses and manageable safety in patients
receive BSC without chemotherapy (irrespective, the non-avelumab-
whosediseasehadprogressedafter(cid:2)2priorlinesofchemother-
containingtreatmentarmwillbereferredtoasthe‘chemotherapy’arm
apy[16].InaphaseIIItrialcarriedoutinAsianpatients,nivolu- hereafter).Allpatientsweretreateduntilprogression,death,intolerable
mabadministeredasthirdorlaterlineoftreatmentimprovedOS toxicity,oranyotherprotocol-definedtreatmentdiscontinuationcriter-
versusplacebo,resultinginapprovalinJapan,Taiwan,andSouth ionwasmet.
Korea for the treatment of unresectable advanced or recurrent
GCprogressingafterchemotherapy[2]. Endpoints
Avelumabisahumananti-PD-L1IgG1monoclonalantibody
Theprimaryobjectivewastodemonstratesuperiorityofavelumabversus
thatisapprovedforadvancedurothelialcarcinomaandmetastat- chemotherapyintermsofOS.Keysecondaryobjectivesincludedcom-
icMerkelcellcarcinomaandhasdemonstratedefficacyinvarious paringprogression-freesurvival(PFS)andobjectiveresponserate(ORR)
Volume29 | Issue10 | 2018 doi:10.1093/annonc/mdy264 | 2053
Original article
Annals ofOncology
perindependentreviewcommittee(IRC)assessment,aswellassafety/ Efficacy
tolerability. Exploratory objectives included assessing duration of and
The intention-to-treat population (all patients randomised to
timetoresponseandevaluatingtumourshrinkageoftargetlesionsfrom
baseline,diseasecontrolrate(DCR),andtumourcellPD-L1expression studytreatment)comprisedall371randomisedpatients.Median
levelsinrelationtoresponseparameters(DCR,ORR,PFS,andOS). OS,theprimaryendpoint,was4.6months(95%CI3.6–5.7)in
theavelumabarmcomparedwith5.0months(95%CI4.5–6.3)
Assessments inthechemotherapyarm[HR¼1.1(95%CI0.9–1.4);P¼0.81]
(Figure2).Therewerenostatisticallysignificantdifferencesbe-
On-treatmentdecisionsweremadeatthediscretionoftheinvestigator
tween the irinotecan and paclitaxel chemotherapy subgroups
(includingdiscontinuationfromstudytreatment),whereasassessments
reportedherearebasedonablindedIRC.PFSandobjectiveresponse (supplementary Figure S1, available at Annals of Oncology on-
wereassessedperRECISTv1.1byanIRC[21].Adverseevents(AEs)were line).Whenassessingsolelypatientswithdiseasecontrol,median
evaluated using the NCI-CTCAE v4.03 (see supplementary methods, OS favoured avelumab [12.5months (95% CI 7.8–17.8) versus
availableatAnnalsofOncologyonline). 8.0months(95%CI7.0–11.0)].
MedianPFSwas1.4months(95%CI1.4–1.5)intheavelumab
Statistics armand2.7months(95%CI1.8–2.8)inthechemotherapyarm
[HR¼1.73(95%CI1.4–2.2);P>0.99].
Thesamplesizeforthistrialwasselectedtoprovide90%powertodem-
onstrate improvement of 2months of median OS time from 4 to SubgroupanalysesofOSaccordingtobaselinedemographics
6months[theprimaryendpoint;equivalenttoahazardratio(HR)of and disease characteristics, including PD-L1 expression, dis-
0.67attheone-sided2.5%overallsignificancelevel].Theprimaryana- playednosignificantdifferencesfavouringeithertreatmentarm,
lysisofcomparingOSbetweentreatmentgroupsusedastratified,one- while PFS subgroup analyses consistently favoured the chemo-
sidedlog-ranktestontheintention-to-treatpopulationandwasplanned therapy arm (supplementary Figures S2 and S3, available at
forwhen256OSeventshadoccurredandfollow-upwas(cid:2)6months.The
AnnalsofOncologyonline).
stratification factor of region (Asia versus non-Asia) was used for the
The confirmed ORR was 2.2% (n¼4, 95% CI 0.6–5.4) and
stratifiedstatisticalanalysisoftheprimaryandkeysecondaryendpoints.
4.3%(n¼8,95%CI1.9–8.3)intheavelumabandchemotherapy
Time-to-event end points were estimated with the Kaplan–Meier
arms, respectively (Table 2). At data cut-off, eight patients had
method,andconfidenceintervals(CIs)forthemedianswerecalculated
usingtheBrookmeyer–Crowleymethod. ongoing responses in the avelumab (n¼3) and chemotherapy
(n¼5) arms. ORRs by patient subgroup are shown in supple-
mentaryTableS2,availableatAnnalsofOncologyonline.Median
Results timetoresponsewas12.2weeks(range5.7–17.6)intheavelumab
arm and 11.6weeks (range 4.3–23.6) in the chemotherapy arm
Patientsdemographicsandtreatmentduration (supplementary Figure S4, available at Annals of Oncology on-
line). Median duration of response was not determined (range
Between 28 December 2015 and 13 March 2017, 459 patients 1.4–5.5) and 5.5months (range 1.5–7.0) in the avelumab and
werescreenedforparticipation,and371wereenrolled(Figure1). chemotherapyarms,respectively.TheORRwassimilarinanex-
Of the 371 enrolled patients, 185 and 186 patients were rando- ploratory post hoc analysis of only randomised patients with
misedtotheavelumabandchemotherapyarms,respectively.In measurablediseaseatbaseline(2.0%versus4.6%intheavelumab
thechemotherapyarm,120(64.5%)patientsreceivedirinotecan, andchemotherapyarms,respectively).
54(29.0%)paclitaxel,and3patients(1.6%)receivedBSConly.
Patient demographics and disease characteristics were generally Safety
balanced between arms (Table 1). Notably,93 patients(25.1%)
The safety analysis set (all patients who were administered any
wereenrolledinAsiancountries.
dose of study treatment or BSC only) comprised 184 patients
Atdatacut-off(14September2017),mediandurationoftreat-
treatedwithavelumaband177patientstreatedwithchemother-
ment in the avelumab arm was 8.0weeks (range 2–66) and
apy.Treatment-relatedAEs(TRAEs)ofanygradeoccurredin90
patients received a median of 3 doses (range 1–31), while the
patients(48.9%)intheavelumabarmand131patients(74.0%)
chemotherapyarmhadmediantreatmentdurationof9.0weeks
inthechemotherapyarm(Table3).Grade(cid:2)3TRAEsoccurred
(range4–58)andpatientsreceivedamedianof5doses(range1–
in 17 patients (9.2%) in the avelumab arm and 56 patients
39).Mediandurationoffollow-upwas10.6monthsinboththe (31.6%)inthechemotherapyarm.
avelumab (range 0.1–17.8) and chemotherapy (range 0.0–17.6) TRAEsledtodiscontinuationinsevenpatients(3.8%)inthe
arms.Twentypatients(5.4%)werestillreceivingstudytreatment avelumab arm and nine patients (5.1%) in the chemotherapy
[10(5.4%)ineacharm]atdatacut-off.Diseaseprogressionwas arm.Deathrelatedtotreatment occurredinonepatient(0.6%;
themostcommonreasonfordiscontinuationinboththeavelu- sudden death) in the chemotherapy arm; there were no
mab [n¼139 (75.1%)] and chemotherapy [n¼134 (72.0%)] treatment-related deaths in the avelumab arm. Following com-
arms.Post-treatmentanticancerdrugtherapywasreceivedby58 prehensive medical review, 12 patients (6.5%) were found to
patients (31.3%) and 66 patients (35.4%) in the avelumab and haveanimmune-relatedAEwithavelumab,whichwasgrade(cid:2)3
chemotherapy arms, respectively; the use of post-progression in 4patients (2.2%; autoimmune hepatitis, autoimmune hypo-
chemotherapywasbalancedbetweenarms(supplementaryTable thyroidism, colitis, and elevated AST). Treatment-related infu-
S1, available at Annals of Oncology online). Seventeen patients sion-related reactions, as evaluated according to a composite
(9.4%)haddetectableantidrugantibodiesintheavelumabarm. definition of preferred terms including signs and symptoms,
2054 | Bangetal. Volume29 | Issue10 | 2018
Original article
Annals ofOncology
Screened for eligibility (n=459)
Excluded prior to randomisation (n=88)
(cid:129) Did not meet all eligibility criteria (n=66)
(cid:129) Withdrew informed consent (n=8)
(cid:129) Adverse event (n=6)
(cid:129) Death (n=6)
(cid:129) Other reason (n=2)
Randomised (N=371)
Avelumab (n=185) Chemotherapy (n=186)
No treatment (n=1) No treatment (n=9)
Received avelumab (n=184) Received irinotecan (n=120)
Treatment ongoing (n=10)a Received paclitaxel (n=54)
Discontinued study treatment (n=174) Received BSC only (n=3)
(cid:129) Adverse event (n=9) Treatment ongoing (n=10)a
(cid:129) Lost to follow-up (n=1) Discontinued study treatment (n=164)
(cid:129) Protocol noncompliance (n=2) (cid:129) Adverse event (n=8)
(cid:129) Death (n=13) (cid:129) Lost to follow-up (n=0)
(cid:129) Disease progression (n=139) (cid:129) Protocol noncompliance (n=1)
(cid:129) Withdrew informed consent (n=9) (cid:129) Death (n=9)
(cid:129) Other (n=1) (cid:129) Disease progression (n=134)
Discontinued treatment and still in (cid:129) Withdrew informed consent (n=6)
follow-up (n=24)
(cid:129) Other (n=6)
Discontinued treatment and still in
ITT population (n=185) follow-up (n=30)
(cid:129) Number of patients in safety
analysis set (n=184)
ITT population (n=186)
(cid:129) Number of patients with available PD-L1
(cid:129) Number of patients in safety
expression status (n=157)
analysis set (n=177)
(cid:129) Number of patients with available PD-L1
expression status (n=160)
Figure 1. CONSORT diagram. aAs of 14 September 2017. BSC, best supportive care; ITT, intention-to-treat; PD-L1, programmed death
ligand-1.
occurred in 39 (21.2%) and 5 (2.8%) patients in the avelumab treatment of GC/GEJC, did not meet its primary end point of
andchemotherapyarms,respectively. improving OS or the secondary end points of PFS and ORR.
AvelumabshowedclinicalactivityinpatientswithGC/GEJCpre-
viouslytreatedwithtwopriorregimensforadvanceddisease,al-
though not superior to chemotherapy; moreover, the safety
Discussion
profileofavelumabwassuperiortothatofchemotherapy.
The JAVELIN Gastric 300 trial, the first study to compare an The first reported phase III trial of a PD-1/PD-L1 agent in
anti-PD-L1antibody(avelumab)tochemotherapyinthird-line advanced GC/GEJC was ATTRACTION-2 (NCT02267343),
Volume29 | Issue10 | 2018 doi:10.1093/annonc/mdy264 | 2055
Original article
Annals ofOncology
Table1.Selectbaselinecharacteristicsintheintention-to-treatpopulation
Characteristics Avelumab Chemotherapy
(n5185) (n5186)
Age,median(range),years 59(29–86) 61(18–82)
Sex
Male 140(75.7) 127(68.3)
Female 45(24.3) 59(31.7)
ECOGPS
0 66(35.7) 62(33.3)
1 119(64.3) 124(66.7)
Histology
Tubular 67(36.2) 66(35.5)
Signetring 42(22.7) 36(19.4)
Mucinous 15(8.1) 21(11.3)
Papillary 3(1.6) 5(2.7)
Other 57(31.3) 58(31.2)
Missing 1(0.5) 0
Tumoursite
Gastric 122(65.9) 138(74.2)
Gastro-oesophagealjunction 63(34.1) 48(25.8)
Geographicregion
Europe 111(60.0) 114(61.3)
Asia 46(24.9) 47(25.3)
NorthAmerica 14(7.6) 11(5.9)
Restoftheworld 14(7.6) 14(7.5)
Race
White 119(64.3) 117(62.9)
Asian 47(25.4) 47(25.3)
Black 1(0.5) 1(0.5)
Notcollected/missing 18(9.7) 21(11.4)
Timesincediagnosisofmetastaticdisease,median(range),months 13.6(2–106) 13.9(3–64)
Numberofprioranticancertherapiesforlocallyadvanced/metastaticdisease
1a 26(14.1) 22(11.8)
2 158(85.4) 161(86.6)
3 0 1(0.5)
(cid:2)4 0 0
Missing 0 2(1.1)
PD-L1status,(cid:2)1%stainingthresholdontumourcells
Positive 46(29.3) 39(24.4)
Negative 111(70.7) 121(75.6)
Dataarenumberofpatients(%)unlessspecifiedotherwise.
aPatientswhoprogressedonneoadjuvanttherapywithoutreceivingsurgeryoradjuvanttherapywithin6monthsoftreatmentdiscontinuationwerecon-
sideredtohavereceivedonelineofpriortreatmentofadvanced,inoperabledisease.
ECOGPS,EasternCooperativeOncologyGroupperformancestatus;PD-L1,programmeddeathligand-1.
whichusedaplaceboinsteadofanactivecomparatorinthecon- progression after platinum and fluoropyrimidine doublet ther-
trol arm. In ATTRACTION-2, nivolumab demonstrated super- apy, failed to meet its primary end point of OS [9.1 versus
iorityinOS[5.26versus4.14months;HR¼0.63(95%CI0.51– 8.3months; HR ¼0.82 (95% CI 0.66–1.03); P¼0.042 (one-
0.78);P<0.0001]comparedwithplaceboasthirdorlaterlineof sided)] in patients with a PD-L1 combined positive score (cid:2)1
therapy in Asian patients with advanced GC/GEJC [2]. [22].Toourknowledge,JAVELINGastric300andKEYNOTE-
KEYNOTE-061 (NCT02370498), a randomised, phase III trial 061aretheonlyrandomisedtrialscomparinganti-PD-1/PD-L1
comparing pembrolizumab with paclitaxel as second-line treat- antibodieswithchemotherapyinpatientswithpreviouslytreated
ment in patients with advanced GC/GEJC and disease GC/GEJC. Although not approved for use in the third-line
2056 | Bangetal. Volume29 | Issue10 | 2018
0 10 11 12 13 14 15 16 17
Time since treatment initiation, months
setting, chemotherapy is frequently used on the basis of several not shown astrong link between prognosis and tumour PD-L1
studies that have suggested improved patient outcomes relative expressioninpatientswithGC/GEJC[13].Potentialdifferences
toBSCorplacebo[23]. in patient cohorts, immunohistochemistry methods, and end
GC/GEJC is biologically heterogeneous, which increases the pointsmayaccountforthesefindings.
difficultyoftreatment.However,wedidnotfindevidenceofclin- Another important finding from our study is that fewer
icalbenefitcomparedwithcommonlyusedchemotherapyinany patientshadTRAEswithavelumabthanwithchemotherapy(ei-
oftheexaminedsubgroups,includingtumourPD-L1expression ther any-grade or grade (cid:2)3 TRAEs). These results demonstrate
status.Furthermore,theimpactofPD-L1expressiononprogno- thatavelumabisbettertoleratedthanchemotherapyinpatients
sisinadvancedGC/GEJCisnotcompletelyclear.Recentfindings with heavily pretreated GC/GEJC, supporting the potential of
fromameta-analysissuggestedthatPD-L1expressionlevelsare avelumabforcombinationormaintenancetherapy,eveninlater
associatedwithOS[24].Conversely,thisstudyandothershave stages of disease. Nevertheless, the optimal strategy for
%
,lavivrus
llarevO
100
Median OS, 6-month OS
months (95% CI) rate (95% CI)
90
Avelumab 4.6 41.0%
80 (n = 185) (3.6–5.7) (33.7–48.1)
70 Chemotherapy 5.0 45.0%
(n = 186) (4.5–6.3) (37.6–52.1)
60
50
40
30
20
Avelumab
10
Chemotherapy
0
1 2 3 4 5 6 7 8 9 18
Number at risk
Avelumab 185 169 142 116 94 83 71 52 38 35 26 18 15 12 9 3 1 1 0
Chemotherapy 186 176 158 138 117 88 73 52 40 30 24 16 9 7 4 3 2 1 0
0
Time since treatment initiation, months
%
,lavivrus
eerf-noissergorP
Original article
Annals ofOncology
A
B
100
Median PFS, 3-month PFS
months (95% CI) rate (95% CI)
90
Avelumab 1.4 19.1%
80 (n = 185) (1.4–1.5) (13.5–25.5)
70 Chemotherapy 2.7 39.2%
(n = 186) (1.8–2.8) (31.3–46.9)
60
50
40
30
20
Avelumab
10
Chemotherapy
0
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Number at risk
Avelumab 185 145 46 28 24 17 14 9 8 5 4 4 2 2 0
Chemotherapy 186 162 84 51 45 29 21 16 11 8 4 2 2 0 0
Figure2.Kaplan–Meierplotsofmedian(A)overallsurvival(OS)and(B)progression-freesurvival(PFS)intheintention-to-treatpopulation
(n¼371).
Volume29 | Issue10 | 2018 doi:10.1093/annonc/mdy264 | 2057
Original article
Annals ofOncology
incorporatingcheckpointinhibitorsintothecontinuumofcare
Table2.ConfirmedresponserateperIRCintheintention-to-treat
forpatientswithadvancedGC/GEJCisstillunknown,andstud-
population
iesofalternativeanti-PD-1/PD-L1treatmentstrategiesinearlier
Avelumab Chemotherapy linesoftherapyarewarranted.
n5185 n5186 Ongoing randomised, phase III trials for advanced GC/GEJC
evaluating checkpointinhibitors in the first-line setting include
Bestobjectiveresponse,n(%)a
CheckMate649(NCT02872116),comparingnivolumabplusipi-
CR 1(0.5) 1(0.5)
limumabversusnivolumabplusinvestigator’schoiceofchemo-
PR 3(1.6) 7(3.8)
therapy (XELOX or FOLFOX) versus chemotherapy alone.
SD 30(16.2) 62(33.3)
ATTRACTION-4(NCT02746796)isaphaseII/IIItrialevaluat-
Non-CR/non-PD 7(3.8) 12(6.5)
ingnivolumabpluschemotherapy(oxaliplatinpluseitherS-1or
PD 94(50.8) 59(31.7)
capecitabine) versus chemotherapy alone in Asian patients.
Non-evaluableb 50(27.0) 45(24.2)
KEYNOTE-062 (NCT02494583) is comparing pembrolizumab
ORRc(95%CI),%d 2.2(0.6–5.4) 4.3(1.9–8.3)
asmonotherapyorincombinationwithcisplatin/5-FU(orcape-
Diseasecontrolrate(95%CI),%e 22.2(16.4–28.8) 44.1(36.8–51.5)
citabine) versus cisplatin/5-FU (or capecitabine) alone as treat-
aClinical activity of best objective response based on confirmed ment of patients with PD-L1þ tumours. JAVELIN Gastric 100
responses. (NCT02625610), a randomised, phase III trial is comparing
bNon-evaluableincludes‘missing’and‘notassessable’. single-agentavelumabadministeredafterpatientsreceiveatleast
cObjective response rate is defined as the proportion of patients with stablediseasewith3monthsoffirst-lineplatinum-basedchemo-
bestobjectiveresponseofCRorPR. therapyasswitch-maintenancetreatmentversuscontinuationof
d95%confidenceintervalusingtheClopper–Pearsonmethod. chemotherapy.
eDiseasecontrolrateisCRþPRþSD(includingnon-CR/non-PD). Resultsfrom theserandomised,controlledtrials willcontrib-
CR,completeresponse;IRC,independentreviewcommittee;ORR,objective utetotheunmetneedfortherapeuticefficacyandsafetydatato
responserate;PD,progressivedisease;PR,partialresponse;SD,stabledisease. informstandardisedguidelinesforthemanagementofadvanced
Table3.IncidenceofTRAEs(anygradein>10%orgrade(cid:2)3in>1%)inthesafetyanalysisset
Avelumab(n5184) Chemotherapy(n5177)
Anygrade Grade(cid:2)3 Grade4/5a Anygrade Grade(cid:2)3 Grade4/5b
AnyTRAE 90(48.9) 17(9.2) 1(0.5) 131(74.0) 56(31.6) 13(7.3)
Nausea 12(6.5) 0 0 50(28.2) 2(1.1) 1(0.6)
Diarrhoea 11(6.0) 1(0.5) 0 47(26.6) 6(3.4) 0
Neutropeniac 0 0 0 37(20.9) 23(13.0) 7(4.0)
Alopecia 0 0 0 25(14.1) 0 0
Anaemia 1(0.5) 0 0 24(13.6) 11(6.2) 0
Decreasedappetite 6(3.3) 0 0 24(13.6) 4(2.3) 0
Infusion-relatedreactiond 39(21.2) 1(0.5) 0 5(2.8) 0 0
Asthenia 7(3.8) 1(0.5) 0 22(12.4) 5(2.8) 0
Fatigue 11(6.0) 1(0.5) 0 18(10.2) 2(1.1) 0
Vomiting 8(4.3) 0 0 17(9.6) 2(1.1) 0
DecreasedWBC 0 0 0 13(7.3) 7(4.0) 3(1.7)
ElevatedALT 6(3.3) 3(1.6) 0 7(4.0) 4(2.3) 1(0.6)
ElevatedAST 7(3.8) 4(2.2) 0 6(3.4) 3(1.7) 1(0.6)
Febrileneutropenia 0 0 0 6(3.4) 6(3.4) 1(0.6)
Elevatedbloodalkalinephosphatase 3(1.6) 2(1.1) 0 3(1.7) 2(1.1) 0
ElevatedGGT 4(2.2) 4(2.2) 1(0.5) 2(1.1) 2(1.1) 0
Elevatedlipase 1(0.5) 1(0.5) 0 2(1.1) 2(1.1) 1(0.6)
Suddendeath 0 0 0 1(0.6) 1(0.6) 1(0.6)
Dataarenumberofpatients(%).
Thesafetyanalysissetcomprisedallpatientswhowereadministeredanydoseofthestudymedicationorbestsupportivecareonly.
aAllTRAEswithavelumabweregrade4.
bAllTRAEswithchemotherapyweregrade4,exceptfor1eventofgrade5suddendeath.
cIncludesthepreferredtermsneutropeniaandneutrophilcountdecreased.
dIncludesadverseeventscategorisedasinfusion-relatedreaction,drughypersensitivity,orhypersensitivityreactionthatoccurredonthedayofinfusionor
dayafterinfusion,inadditiontosignsandsymptomsofinfusion-relatedreactionthatoccurredonthesamedayofinfusionandresolvedwithin2days.
ALT,alanineaminotransferase;AST,aspartateaminotransferase;GGT,c-glutamyltransferase;TRAE,treatment-relatedadverseevent;WBC,whitebloodcell.
2058 | Bangetal. Volume29 | Issue10 | 2018
Original article
Annals ofOncology
GC/GEJCandpotentiallyidentifypatientsubgroupsmostlikely Merck Serono, and Foundation Medicine. S-EA-B reports con-
tobenefitfromcheckpointinhibitors. sultancy or advisory role with Bristol-Myers Squibb, Celgene,
Eli Lilly, Merck, Merck Sharp & Dohme, Nordic Pharma, and
Roche; speaker services for AIO gGmbH, Celgene, Eli Lilly,
Acknowledgements
Forum fu¨r Medizinische Fortbildung, MCI, Nordic Pharma,
Theauthorsthank thepatientsandtheirfamilies,investigators, Promedicis, and Roche; is the CEO/Founder of IKF Klinische
co-investigators, and study teams at each of the participating KrebsforschungGmbH;andresearchfundingfromCelgene,Eli
centres, at Merck KGaA, Darmstadt, Germany, and at EMD Lilly, Federal Ministry of Education of Research, German
Serono, Billerica, MA, USA (a business of Merck KGaA, Cancer Aid (Krebshilfe), German Research Foundation,
Darmstadt,Germany). Hospira, Medac, Merck, Roche, Sanofi, and Vifor. NB reports
honoraria from Chugai Pharma, Eli Lilly, Merck KGaA, Ono
Pharmaceutical, Shionogi Pharma, Taiho Pharmaceutical, and
Funding Yakult Honsha, and his institution has received research grants
from Bristol-Myers Squibb, Ono Pharmaceutical, and Taiho
This work was supported by Merck KGaA, Darmstadt,
Pharmaceutical.MHMreportsconsultancyoradvisoryfeesand
Germany, and is part of an alliance between Merck KGaA and
speaker services for Amgen, Bayer, Merck & Co, Merck KGaA,
Pfizer Inc., New York, NY, USA. Medical writing support was
andRocheandhasreceivedtravelexpensesfromAmgen,Merck
provided by ClinicalThinking, Inc., Hamilton, NJ, USA, and
KGaA, and Pfizer. JH and HX and are employees of EMD
funded by Merck KGaA, and Pfizer Inc. No grant number is
Serono, a company of Merck KGaA, Darmstadt, Germany. JH
applicable.
reports personal fees from EMD Serono during the conduct of
the study and outside the submitted work. RH is an employee
ofMerckKGaA,Darmstadt.ICisanemployeeofEMDSerono
Disclosure
and owns stock in Eli Lilly. JT reports honoraria from Amgen,
Y-JB reports consultancy or advisory role with ADC Baxalta, Celgene, Eli Lilly, Merck KGgA, Roche/Genentech,
Therapeutics, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Sanofi, and Servier; consultancy or advisory role with Amgen,
Lilly, Five Prime Therapeutics, Genentech/Roche, Green Cross, Baxalta, Celgene, Eli Lilly, Merck KGgA, Roche/Genentech,
Merck Serono, Merck Sharp & Dohme, Novartis, Ono Sanofi, and Servier; and travel, accommodations, or expenses
Pharmaceutical, Pfizer, Taiho Pharmaceutical, and Samyang from Amgen, Baxalta, Celgene, Eli Lilly, Merck KGgA, Roche/
Biopharm; and research funding from AstraZeneca, Bayer, Genentech, Sanofi, and Servier. All remaining authors have
BeiGene, Boehringer-Ingelheim, Boston Biomedical, Bristol- declarednoconflictsofinterest.
MyersSquibb,CKD,Curis,DaiichiSankyo,EliLilly,FivePrime
Therapeutics, Genentech/Roche, GlaxoSmithKline, Green References
Cross, Hanmi, MacroGenics, Merck Serono, Merck Sharp &
Dohme,Novartis,OnoPharmaceutical,Otsuka,Pfizer,Takeda, 1. NooneAM,HowladerN,KrapchoMetal.SEERcancerstatisticsreview,
1975,2015;https://seer.cancer.gov/csr/1975_2015.
and Taiho Pharmaceutical. EVC reports research funding from
2. KangYK,BokuN,SatohTetal.Nivolumabinpatientswithadvanced
Amgen, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb,
gastricorgastro-oesophagealjunctioncancerrefractoryto,orintolerant
Celgene,EliLilly, Ipsen,Merck,MerckKGaA, Novartis, Roche,
of, at least two previous chemotherapy regimens (ONO-4538-12,
and Servier. K-WL reports consultancy or advisory role with ATTRACTION-2): a randomised, double-blind, placebo-controlled,
Merck KGaA, and Sanofi/Aventis; and research funding from phase3trial.Lancet2017;390(10111):2461–2471.
AstraZeneca/MedImmune, Daiichi Sankyo, Five Prime 3. WagnerAD,SynNL,MoehlerMetal.Chemotherapyforadvancedgas-
Therapeutics, Green Cross, MacroGenics, Merck KGaA, Merck triccancer.CochraneDatabaseSystRev2017;8:CD004064.
4. DigkliaA,WagnerAD.Advancedgastriccancer:currenttreatmentland-
Sharp & Dohme, Ono Pharmaceutical, and Taiho
scapeandfutureperspectives.WJG2016;22(8):2403–2414.
Pharmaceutical. LW reports consultancy or advisory role with
5. Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical
Amgen, Eisai, Halozyme, and Roche; speaker services for PracticeGuidelinesfordiagnosis,treatmentandfollow-up.AnnOncol
Amgen, Roche, and Sanofi; and travel, accommodations, or 2016;27(Suppl5):v38–v49.
expenses from Roche and Servier. MS reports personal fees 6. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer.
from AbbVie, Astellas, AstraZeneca, Bristol-Myers Squibb, Eli V2.2018; https://www.nccn.org/professionals/physician_gls/pdf/gastric.
pdf(10May2018,datelastaccessed).
Lilly, Merck Serono, Merck Sharp & Dohme, Mylan, Novartis,
7. BangYJ,VanCutsemE,FeyereislovaAetal.Trastuzumabincombin-
Pfizer,andRoche.M-HRreportshonorariafromBristol-Myers
ation with chemotherapy versus chemotherapy alone for treatment of
Squibb, Dae Hwa Pharmaceutical, Eli Lilly, and Ono
HER2-positive advanced gastric or gastro-oesophagealjunction cancer
Pharmaceutical;andconsultancyoradvisorywithBristol-Myers (ToGA):aphase3,open-label,randomisedcontrolledtrial.Lancet2010;
Squibb, Dae Hwa Pharmaceutical, Eli Lilly, and Ono 376:687–697.
Pharmaceutical.HCCreportsconsultancyoradvisoryrolewith 8. SalatiM,DiEmidioK,TarantinoV,CascinuS.Second-linetreatments:
Bristol-MyersSquibb, Celltrion, EliLilly, Merck Serono, Merck movingtowardsanopportunitytoimprovesurvivalinadvancedgastric
cancer?ESMOOpen2017;2(3):e000206.
Sharp&Dohme,Quintiles,andTaihoPharmaceutical;research
9. TaberneroJ,ShitaraK,DvorkinMetal.Overallsurvivalresultsfroma
funding from Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,
phase III trial of trifluridine/tipiracil versus placebo in patients with
Merck Serono, Merck Sharp & Dohme, Ono Pharmaceutical, metastaticgastriccancerrefractorytostandardtherapies(TAGS).Ann
and Taiho Pharmaceutical; and speaker services for Eli Lilly, Oncol2018;29(Suppl5):mdy208.001.
Volume29 | Issue10 | 2018 doi:10.1093/annonc/mdy264 | 2059
Original article
Annals ofOncology
10. Japanese Gastric Cancer Association Japanese gastric cancer treatment 18. NghiemP,BhatiaS,BrohlASetal.Two-yearefficacyandsafetyupdate
guidelines2014(ver.4).GastricCancer2017;20(1):1–19. fromJAVELINMerkel200partA:aregistrationalstudyofavelumabin
11. CancerGenomeAtlasResearchNetwork.Comprehensivemolecularchar- metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin
acterizationofgastricadenocarcinoma.Nature2014;513(7517):202–209. Oncol2018;36(Suppl):abstr9507.
12. AmatatsuM,ArigamiT,UenosonoYetal.Programmeddeath-ligand1 19. ChungH,ArkenauHT,LeeJetal.Avelumab(anti-PD-L1)asfirst-line
isapromisingbloodmarkerforpredictingtumorprogressionandprog- maintenance (1L mn) or second-line (2L) therapy in patients with
nosisinpatientswithgastriccancer.CancerSci2018;109(3):814–820. advanced gastric or gastroesophageal junction cancer (GC/GEJC):
13. KawazoeA, KuwataT, KubokiYet al. Clinicopathologicalfeatures of updatedphaseIbresultsfromtheJAVELINSolidTumortrial.Oralpres-
programmeddeathligand1expressionwithtumor-infiltratinglympho- entationatAmericanAssociationforCancerResearchAnnualMeeting
cyte,mismatchrepair,andEpstein-Barrvirusstatusinalargecohortof 2018,14–18April2018,Chicago,IL,AbstrCT111.
gastriccancerpatients.GastricCancer2017;20(3):407–415. 20. HironakaS,ShitaraK,IwasaSetal.Avelumab(MSB0010718C;anti-PD-
14. YuanJ,ZhangJ,ZhuYetal.Programmeddeath-ligand-1expressionin L1) in Japanese patients with advanced gastric cancer: results from a
advancedgastriccancerdetectedwithRNAinsituhybridizationandits phase1btrial.AnnOncol2016;27(Suppl7):mdw521.047.
clinicalsignificance.Oncotarget2016;7(26):39671–39679. 21. EisenhauerEA,TherasseP,BogaertsJetal.Newresponseevaluationcri-
15. WangL,ZhangQ,NiSetal.Programmeddeath-ligand1expressionin teria in solid tumours: revised RECIST guideline (version 1.1). Eur J
gastriccancer:correlationwithmismatchrepairdeficiencyandHER2- Cancer2009;45(2):228–247.
negativestatus.CancerMed2018;7(6):2612–2620. 22. ShitaraK,OzgurogluM,BangYJetal.Pembrolizumabversuspaclitaxel
16. FuchsCS,DoiT,JangRWetal.Safetyandefficacyofpembrolizumab forpreviouslytreated,advancedgastricorgastro-oesophagealjunction
monotherapy in patients with previously treated advanced gastric and cancer(KEYNOTE-061):arandomised,open-label,controlled,phase3
gastroesophagealjunctioncancer:phase2ClinicalKEYNOTE-059Trial. trial.Lancet2018;392(10142):123–133.
JAMAOncol2018;4(5):e180013. 23. ZhengY,ZhuXQ,RenXG.Third-linechemotherapyinadvancedgastric
17. PatelMR,EllertonJ,InfanteJRetal.Avelumabinmetastaticurothelial cancer: a systematic review and meta-analysis. Medicine (Baltimore)
carcinomaafterplatinumfailure(JAVELINSolidTumor):pooledresults 2017;96(24):e6884.
fromtwoexpansioncohortsofanopen-label,phase1trial.LancetOncol 24. GuL,ChenM,GuoDetal.PD-L1andgastriccancerprognosis:asys-
2018;19(1):51–64. tematicreviewandmeta-analysis.PLoSOne2017;12(8):e0182692.
2060 | Bangetal. Volume29 | Issue10 | 2018
